Cambridge Display Technology 3Q revenue, profits down as industry R&D spending slows

Cambridge Display Technology, Inc. (OLED), a pioneer in the development of polymer light emitting diode (P-OLED) technology, said on Friday that both its revenue and gross profits were down in the third ended September 30.

Total revenues were $0.9m, down from $6.6m for the same period in 2005 when it sold three inkjet printers and two large technology services and development contracts.

Gross profit was $0.4m, compared with $2.9m.

Chairman and CEO Dr. David Fyfe (pictured) said: “Although our financial results continue to be impacted by the slow-down in discretionary R&D spending in the display industry, we completed a major license deal in September for which we expect to recognize significant revenues in future periods and we have continued to achieve significant improvements in P-OLED material lifetimes.

“During the third quarter, we were delighted to see one of our long-term licensees, MicroEmissive Displays, announce that it had raised funding for the construction of a volume manufacturing facility for its P-OLED microdisplay products. This facility will be located in Germany and is due to commence production in mid-2007.''

Sao Paulo deal

He said the Cambridge-headquartered, NASDAQ listed-CDT will be appointed by a consortium of Brazilian state agencies and a private developer to carry out a feasibility study for a P-OLED manufacturing facility in Sao Paulo. The funding for this study was agreed at a signing this week.

The group’s share price fell $1.40, or 18%, after the release of the results to finish at $6.19 on heavy volume on Friday.

Q3 2006 net loss was $9.6m, compared with $8.6m for the same period in 2005. Cash used in operations was $6.8m, compared with cash used of $7.6m. The cash and near cash total was $15.6m at September 30, compared with $31.3m at the end of December 2005.

13th November 2006

Previous articles
Briefs: CamiSemi raises an extra $8m in round C funding; Alizyme US partner starts Phase 2 clinical trials for ulcerative colitis drug
Regulatory compliance spurs strong sales growth in Plasmon's UDO Archive Appliance
Acambis surprised as US Govt rejects smallpox vaccine proposal
Shift of focus, new CEO for Sagentia; to switch to AIM: losses widened in 07
Cambridge's SQW, Oxford Innovation merge: aim for IPO in 2 to 3 years
Population Genetics raises £3.8m in Series A funding; appoints CEO
Snippets: CeNeS in offer talks; Celsis sees strong trading
BioProgress buys US-based airPharma for £4.2m; raises £6.15m in share placing
ARM, Adobe partner to boost Internet Apps; awards for CamSemi, Amino
Briefs: University old boys donate £5m for new mother/fetus research centre; Aveva says business remains good
Subscribe

 

Corporate profiles

 • Intercytex


Nick Higgins BSc, MSc
Chief Executive Officer


Intercytex is an emerging healthcare developer of cell therapy products for the woundcare and aesthetic medicine markets. It is using its proprietary expertise in cell therapy to develop products that harness the innate ability of human cells to regenerate and repair the body. Intercytex commenced

[Intercytex's profile]


Top20 Index




Currently: 71.78


Create Publisher Site
This Publisher Website ( slot3.siliconfenbusiness.com ) does not exist in Direct-Link-Ads.com. Please create it now.